Gregory D. Perry - 17 Jun 2021 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Reporting relationship: Director
Issuer ticker: KALA
Reported as of: 17 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2021, 17:30:57 UTC
Prior SEC filing: 02 Jun 2021
Next SEC filing: 28 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Mary Reumuth, Attorney-in-Fact

Key filing fact

Gregory D. Perry filed Form 4 for Kala Pharmaceuticals, Inc. (KALA) on 21 Jun 2021.

Key facts

This page summarizes Gregory D. Perry's Form 4 filing for Kala Pharmaceuticals, Inc. (KALA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Jun 2021, 17:30.

Change

Previous filing in this sequence was filed on 02 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALA transaction

Common Stock

Award

Transaction value: $0
Shares: +20,000
Change %: +100%
Price: $0.000000
Shares after: 40,000
Date: 17 Jun 2021
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021.

Footnote F2

Includes 20,000 unvested RSUs.